Full description
A randomised, double-blind, controlled trial to assess the effect of xanthine oxidase inhibitor, allopurinol, on the glomerular filtration rate (eGFR) in patients with stage 3-4 Chronic Kidney Disease Chronic kidney disease (CKD), defined as an eGFR less than 60 ml/min/1.73 m2 and/or the presence of kidney damage (albuminuria or proteinuria) for at least 3 months, is a major public health problem affecting approximately 1.6 million Australian adults. Of these affected individuals, approximately 930,000 have stages 3-4 CKD (eGFR 15-60 mL/min/1.73 m2). CKD patients have a greatly increased risk of adverse renal and cardiovascular (CV) outcomes, even in its early stages. CKD patients are at increased risk of progression to end-stage kidney disease (ESKD). The incidence of ESKD is increasing in Australia by 6% per annum. Apart from an increased risk of ESKD, the presence of CKD is one of the most potent known risk factors for cardiovascular disease (CVD), such that individuals with CKD are more likely to die, mostly from CVD, than survive to the point of needing dialysis or kidney transplantation. A reduction in eGFR < 60 ml/min/1.73 m2 is associated with increased risks of all-cause and CV mortality. The CKD-FIX trial aims to critically examine the efficacy and safety of allopurinol as an agent to slow the progression of chronic kidney disease (CKD).Notes
HeSANDA 1.0.0Collected: 2014-03-21
Collected: 2019-01-22
Data time period: 2014 to ,
Data time period: 2019 to ,
Spatial Coverage And Location
text: ACT
text: NSW
text: QLD
text: SA
text: TAS
text: WA
text: VIC
Subjects
Biomedical and Clinical Sciences |
Chronic Kidney Disease |
Clinical Sciences |
Nephrology and Urology |
User Contributed Tags
Login to tag this record with meaningful keywords to make it easier to discover
Other Information
National Health and Medical Research Council
Identifiers
- DOI : 10.60540/LB9L7D